HOME >> BIOLOGY >> NEWS
Gene Shears In Cutting Edge Anti-Aids Trial

CSIRO's revolutionary "gene shears" technology has entered clinical trials in adults as the first step in developing a potential treatment for the human immunodeficiency virus (HIV) which causes AIDS, the chief executive of Gene Shears Pty Ltd, Dr Leigh Farrell announced today.

The Phase One clinical trial, conducted at St Vincent's Hospital, Sydney, is testing the safety and ability of Gene Shears' patented gene therapy to inhibit HIV replication in infected patients.

HIV attacks a special class of white blood cell, the CD4+ lymphocyte, which forms the backbone of the human immune defence against attacks by infection. Loss of these white blood cells causes the immune system eventually to break down.

The basis for the trial is the original discovery by CSIRO Plant Industry molecular biologists Dr Jim Haseloff and Dr Wayne Gerlach that naturally-occurring enzymes called ribozymes (dubbed "gene shears") can be used selectively to chop up pieces of genetic material. Gene Shears Pty Ltd went on to prove in laboratory experiments that ribozymesit could be used to prevent the replication of HIV by cutting its genetic material.

The chief executive of CSIRO, Dr Malcolm McIntosh, welcomed news that human trials of the anti-HIV gene shears were under way. "It is extremely pleasing that this fundamental Australian discovery is now starting to bear fruit in the form of practical applications which promise to improve human health and wellbeing," he said.

"It highlights the national importance of CSIRO continuing to perform excellent basic science designed to gain new knowledge."

The Sydney experiment involves six pairs of identical twins, of whom one of each pair is HIV-positive.

CD4+ white blood cells taken from the uninfected twin are equipped with the anti-HIV ribozyme and then infused into the HIV-infected twin.

The trial seeks first to establish that the ribozyme is safe and has no side-effects on the patien
'"/>

Contact: Dr Leigh Farrell
genes@ozemail.com.au
61-2-9878-8200
CSIRO Australia
4-Aug-1997


Page: 1 2

Related biology news :

1. Cutting-edge cancer researchers sought for international recognition
2. Cutting back on cigarettes: when less is more
3. AChemS: Cutting edge research in taste, smell, & chemical irritation
4. Cutting edge
5. Cutting-edge research to be presented at ASCPT pharmacology conference
6. Cutting the risk of coronary disease - start before birth says UK doctor
7. Story Tips: Engineering Students Pursue Cutting-Edge Research
8. Brain Building May Depend On DNA Cutting And Pasting
9. Cutting The Time And Cost Of Developing New Cures: Lord Sainsbury Launches Worlds First Biomedical Accelerator Mass Spectrometer In York
10. Flexibility In Cutting Toxic Releases Yields Dividends
11. Trial shows which brain cancer patients benefit from temozolomide

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... 2017 AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: ... aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... the listing of its common shares on the NASDAQ ... "AquaBounty,s listing on NASDAQ represents an important ... to the U.S. markets as we advance plans for ...
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , the leading ... the world, was today awarded the "Best Science & Technology Social Networking Service ... and decided upon by a dedicated team of researchers and analysts. , The ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
Breaking Biology Technology:
Cached News: